logo
Share SHARE
FONT-SIZE Plus   Neg

Astellas Pharma Says FDA Advisory Committee Recommends Approval Of Mirabegron

Astellas Pharma US, Inc., a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (ALPMY.PK, ALPMF.PK), announced that the Reproductive Health Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) voted that the overall risk/benefit assessment supports approval of mirabegron (YM178) for the treatment of overactive bladder (OAB) (Yes: 7, No: 4, Abstain: 1).

Today's committee recommendation, although not binding, will be considered by the FDA as it reviews the New Drug Application or NDA, the company said. The FDA is expected to issue an action letter on the mirabegron application by June 29, 2012.

Mirabegron is a once daily oral selective B3-adrenoceptor agonist discovered and developed by Astellas. Mirabegron has been studied extensively in more than 10,000 individuals over the last 10 years.

Mirabegron uses a distinct mechanism of action versus antimuscarinics, the current treatment standard. Antimuscarinics work by binding to muscarinic receptors in the bladder and inhibiting involuntary bladder contractions. Mirabegron works by stimulating the B3 receptors in the detrusor muscle of the bladder, causing relaxation of the bladder muscle during the storage phase of the micturition (urination) cycle. This improves the storage capacity of the bladder without diminishing bladder contraction during bladder voiding.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
French conglomerate Bouygues SA reported Thursday a net loss for the first half compared to a profit last year, which was boosted by a gain on Cofiroute unit stake sale. However, sales edged up 1 percent from last year. The company raised its 2015 outlook for Bouygues Telecom and confirmed its forecast for the construction businesses and TF1 television business. Kraft Heinz is recalling more than two million pounds of Oscar Mayer turkey bacon as it may prematurely spoil and on reports of people becoming unwell after eating certain items. Apparel maker PVH Corp. said Wednesday after the markets closed that its second quarter profit fell 19% from last year, hurt mainly by a stronger U.S. dollar. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations as did its quarterly revenue. As a result, the company once again raised its full year outlook.
comments powered by Disqus
Follow RTT